Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$3.99
-$0.02(-4.12%)
At close: 4:00 PM EST
$3.99
-$0.02(-4.12%)
Day’s Range― - ―
52-Week Range$0.25 - $7.35
Previous CloseN/A
Volume102.01K
Average Volume (3M)24.86M
Market Cap
$6.87M
Enterprise Value$7.64M
Total Cash (Recent Filing)$1.23M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 07, 2026EPS Estimate
-1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.94
Shares Outstanding1,596,849
10 Day Avg. Volume1,119,088
30 Day Avg. Volume24,857,414
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit1.17
Enterprise Value/Ebitda-12.64
Forecast
1Y Price Target
$5.00Price Target Upside25.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.76
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Revenue ReboundThe company reports very high gross margins on recent revenue, indicating strong unit economics from its biologic programs. Durable high product-level margins support long-term margin scalability and attractive partner economics for licensing or manufacturing collaborations as clinical programs advance.
Regained Cell-therapy License RightsRecovering commercial-ready rights to HCW9201/HCW9206 repositions the company to capture value from growing CAR-T and NK-cell markets. Owning these assets enables direct partnerships, licensing, or CMO supply opportunities that can create durable revenue streams beyond current clinical-stage programs.
Settled Disputes And Removed LiensEliminating $2.8M of disputed liabilities and a $1.1M lien clears legal encumbrances on key infrastructure and improves balance-sheet clarity. This structural cleanup reduces operational risk, frees collateral, and strengthens vendor relationships critical for sustained R&D and GMP manufacturing access.
Bears Say
Deep Negative Cash FlowSustained negative operating and free cash flow of roughly $11.5M TTM implies ongoing cash consumption that will require repeated external financing. This structural cash-burn constrains runway, forces dilution or debt raises, and can delay clinical milestones if capital access tightens.
Persistent Operating LossesAn EBIT margin near -77% shows the business is not yet operationally scalable; high R&D and G&A outweigh revenues. Continued large losses reduce internal funding capacity, prolong dependence on external capital, and mean profitability remains a multi-period objective dependent on clinical and commercial success.
Nasdaq Monitoring And Listing RiskExtended Nasdaq monitoring and reverse-split actions create sustained governance pressure and raise the stakes for meeting bid-price thresholds. Loss of listing or renewed deficiencies would materially impair access to public capital and investor liquidity, heightening structural financing and strategic risk.
HCW Biologics News
HCWB FAQ
What was Hcw Biologics, Inc.’s price range in the past 12 months?
Hcw Biologics, Inc. lowest stock price was $0.25 and its highest was $7.35 in the past 12 months.
What is Hcw Biologics, Inc.’s market cap?
Hcw Biologics, Inc.’s market cap is $6.87M.
When is Hcw Biologics, Inc.’s upcoming earnings report date?
Hcw Biologics, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 34 days.
How were Hcw Biologics, Inc.’s earnings last quarter?
Hcw Biologics, Inc. released its earnings results on May 14, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of N/A by $0.37.
Is Hcw Biologics, Inc. overvalued?
According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Undervalued.
Does Hcw Biologics, Inc. pay dividends?
Hcw Biologics, Inc. does not currently pay dividends.
What is Hcw Biologics, Inc.’s EPS estimate?
Hcw Biologics, Inc.’s EPS estimate is -1.98.
How many shares outstanding does Hcw Biologics, Inc. have?
Hcw Biologics, Inc. has 1,596,849 shares outstanding.
What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?
Hcw Biologics, Inc. reported an EPS of $0.37 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 262.018%.
Which hedge fund is a major shareholder of Hcw Biologics, Inc.?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hcw Biologics, Inc.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$5.00
▲(25.31% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
54.89% Insiders
1.55% Mutual Funds
21.79% Other Institutional Investors
21.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---